20-F: Belite Bio Files 20-F Annual Report for Fiscal Year 2024

Belite Bio, Inc. releases its 20-F filing, detailing financial results and operational activities for the year ended December 31, 2024.

Summary

• Belite Bio, Inc., a clinical-stage biopharmaceutical company, has filed its 20-F annual report for the fiscal year ended December 31, 2024.
• The company focuses on developing novel therapeutics for degenerative retinal diseases, including Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA).
• Belite Bio's lead product candidate, Tinlarebant, is an orally administered treatment for STGD1 and GA.
• The company's drug development pipeline also includes LBS-009, a small molecule for metabolic diseases like NAFLD, NASH, and T2D.
• Belite Bio has incurred net losses since inception and anticipates continuing to do so for the foreseeable future.
• The company's net losses were approximately US$12.6 million, US$31.6 million and US$36.1 million for the years ended December 31, 2022, 2023 and 2024, respectively.
• As of December 31, 2024, the company had an accumulated deficit of approximately US$107.6 million.
• Belite Bio expects expenses to increase as it continues clinical trials and seeks marketing approval for its product candidates.
• The company will need to obtain additional funding to finance its operations.
• As of December 31, 2024, the company had cash of approximately US$31.7 million and short-term investments of approximately US$113.5 million.
• The company is conducting a Phase 3 clinical trial (DRAGON) for Tinlarebant in adolescent STGD1 patients and a Phase 3 clinical trial (PHOENIX) for GA associated with dry AMD.
• The company is also conducting a clinical trial of Tinlarebant in adolescent STGD1 patients aged 12 to 20 years old in Japan, the United States and the United Kingdom (DRAGON II).
• The company is dependent on patents, know-how and proprietary technology licensed from others.
• The company is subject to changing legal and regulatory requirements in the PRC pharmaceutical industry.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments in the clinical trials and regulatory designations for Tinlarebant, the company's ongoing net losses and need for additional funding create uncertainty.

Positives

• Tinlarebant has received Orphan Drug Designation in the United States, Europe and Japan, providing market exclusivity.
• Tinlarebant has received Fast Track designation from FDA for the treatment of STGD1, potentially expediting the development and review process.
• Tinlarebant has received Rare Pediatric Disease Designation in the United States and may be eligible for a priority review voucher.
• The company has completed enrollment of 104 subjects in the Phase 3 DRAGON trial.
• The company has dosed the first patient in the Phase 2/3 portion of the DRAGON II trial, which has a target enrollment of approximately 60 subjects, including approximately 10 Japanese subjects.
• The company has enrolled 406 subjects for the Phase 3 PHOENIX trial.

Negatives

• The company has incurred net losses since inception and anticipates continuing to do so for the foreseeable future.
• The company will need to obtain additional funding to finance its operations.
• The company is dependent on patents, know-how and proprietary technology licensed from third parties.
• The company is subject to changing legal and regulatory requirements in the PRC pharmaceutical industry.

Risks

• The company's business is highly dependent on the success of its lead product candidate, Tinlarebant.
• All of the company's product candidates are in clinical or preclinical development.
• The company has a limited operating history and no history of commercializing pharmaceutical products.
• The regulatory approval processes of the FDA, the TGA, the NMPA, the EMA, the PMDA and other comparable regulatory authorities are time-consuming.
• If the company is unable to obtain and maintain patent and other intellectual property protection for its product candidates, third parties could develop and commercialize competing products.
• The company depends on intellectual property licensed from third parties, and its current and future licensors may not always act in its best interest.
• If the company fails to implement and maintain an effective system of internal controls, it may be unable to accurately report its results of operations.
• The company's future success depends on its ability to attract, retain and motivate senior management and qualified scientific employees.
• As the company relies on third parties to conduct its preclinical studies, clinical trials, contract manufacture drug substances and drug products, it may not be able to obtain regulatory approval for or commercialize its product candidates if these third parties fail to perform their duties.
• The company expects to seek to establish collaborations and, if it is not able to establish them on commercially reasonable terms, it may have to alter its development and commercialization plans.
• As a result of the company's principal shareholder, Lin Bioscience International Ltd.'s significant share ownership position in the company, it is able to influence corporate matters and a conflict of interest may arise between the company's principal shareholder and the company.

Future Outlook

The company expects to continue to incur significant expenses and increasing operating losses for the next several years and will need to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources.

Industry Context

The document highlights the competitive landscape in the treatment of STGD1 and GA, noting that while there are no FDA-approved treatments for STGD1 and no FDA-approved orally administered treatments for GA, several companies are in clinical development for their product candidates. This underscores the significant unmet medical need and the potential market opportunity for Belite Bio's therapies.

Comparison to Industry Standards

• The document mentions that the Tinlarebant Phase 3 STGD1 clinical study is the only ongoing Phase 3 clinical trial for STGD1, which positions Belite Bio as a leader in this specific area.
• In GA, there are five other companies advancing treatments, with three companies currently in Phase 3 development, and two companies which have completed Phase 3 development and received drug approval from the FDA for intravitreally injected therapeutic agents. This indicates a competitive but active field with established benchmarks for regulatory success.

Related Party Transactions

• The company entered into research and development services agreements with Lin BioScience, Inc., its ultimate controlling shareholder, for Tinlarebant and LBS-007.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees may benefit from the company's growth and development.
• Patients with STGD1 and GA may benefit from the development of new therapies.

Next Steps

• Continue Phase 3 clinical trials for Tinlarebant in STGD1 and GA.
• Pursue regulatory approvals for Tinlarebant.
• Explore potential collaborations and licensing agreements.
• Continue research and development efforts for LBS-009 and other product candidates.

Key Dates